Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome

Marc Tischkowitz1 · Chrystelle Colas2 · Sjaak Pouwels3 · Nicoline Hoogerbrugge4 · PHTS Guideline Development Group · The European Reference Network GENTURIS

Received: 23 February 2020 / Revised: 16 April 2020 / Accepted: 28 April 2020 / Published online: 12 June 2020 © The Author(s) 2020. This article is published with open access

Abstract

PTEN hamartoma tumour syndrome is a diverse multi-system disorder predisposing to the development of hamartomatous growths, increasing risk of breast, thyroid, renal cancer, and possibly increasing risk of endometrial cancer, colorectal cancer and melanoma. There is no international consensus on cancer surveillance in PHTS and all current guidelines are based on expert opinion. A comprehensive literature review was undertaken and guidelines were developed by clinicians with expertise from clinical genetics, gynaecology, endocrinology, dermatology, radiology, gastroenterology and general surgery, together with affected individuals and their representatives. Recommendations were put forward for surveillance for breast, thyroid and renal cancers. Limited recommendations were developed for other sites including endometrial, colon and skin. The proposed cancer surveillance recommendations for PHTS require a coordinated multidisciplinary approach and significant patient commitment. The evidence base for cancer surveillance in this guideline are limited, emphasising the need for prospective evaluation of the effectiveness of surveillance in the PHTS population.

Introduction

PTEN hamartoma tumour syndrome (PHTS), OMIM 158350, ORPHA:306498, is caused by germline variants that affect function of the PTEN (phosphatase and tensin homologue) gene, henceforth called “pathogenic variants” (PV). It is a diverse multi-system disorder that encompasses Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome and Proteus-like syndrome, individuals with PHTS are at increased risk of breast, thyroid, renal cancer, and possibly endometrial cancer, colorectal cancer and melanoma [1].

The projected estimated lifetime risks of cancer in individuals with PHTS range from 85 to 89% for any cancer, 67 to 85% for female breast cancer, 6 to 38% for thyroid cancer, 2 to 28% for endometrial cancer, 2 to 34% for renal cancer, 9 to 20% for colorectal cancer and 0 to 6% for melanoma [2–6]. These estimates and those given in Table 1 are likely to be at the upper end of the true range because of likely ascertainment bias in studies published to date. Moreover these estimates are projections based on small datasets and have wide confidence intervals. Ultimately, larger prospective longitudinal studies, including those individuals diagnosed in childhood because of developmental problems, and asymptomatic relatives with PTEN PVs, will be needed to define the risk more accurately.

PHTS is rare and its clinical diagnosis relies on characteristic signs and symptoms with variable expressivity, followed by confirmatory genetic testing. Early identification of affected individuals, which often precedes development of advanced cancer by several years, allows appropriate surveillance to be instituted, which is key to timely detection of lesions. Genotype–phenotype analysis...
has not been conclusive. A single study by Tan et al. found a correlation between promoter PVs and breast cancer and between nonsense PVs and colorectal cancer, this remains unconfirmed [6]. There are thus currently no specific PVs established that help to stratify patients for surveillance.

Diagnostic criteria for PHTS have been published and are regularly updated by the National Comprehensive Cancer Network® (NCCN®), 2019). They are divided into major and minor criteria, and various combinations can be used to reach a diagnosis. The availability of these criteria aids clinicians in achieving consistency in clinical case definition. Conversely, gene-specific criteria for the interpretation of PTEN variants have been developed by the ClinGen PTEN Expert Panel [7]. They offer a more bespoke approach to the American College of Medical Genetics variant interpretation guidelines and are a helpful tool for those involved in PTEN variant classification. In this light it is important to keep in mind that historic reports did not interpret variants with the same stringency as is now applied.

Individuals with PHTS are at risk of several different cancers which are amenable to early detection, but surveillance protocols are complex, and there are no data available documenting a consequent reduction in morbidity and mortality, nor evaluating how well surveillance is coordinated across countries. Moreover, there is no international consensus on cancer surveillance in PHTS and all current guidelines are based on expert opinion. Guidelines have been published by the National Comprehensive Cancer Network® (NCCN®), and in the United Kingdom guidelines have been developed for use in the National Health Service by the UK Cancer Genetics Group. Here we propose guidelines for member states of the European Union which could also be used by other countries.

### Scope of the guidelines

This guideline is intended to address cancer surveillance of individuals with PHTS and has been elaborated by members of the European Reference Network (ERN) for Genetic Tumour Risk Syndromes (GENTURIS). It aims specifically to integrate available information to assist healthcare professionals in evidence-based surveillance of individuals with a confirmed germline pathogenic variant in PTEN. It addresses surveillance for increased risk of cancer tailored to tumour site, offers guidance on the imaging modality that should be used for surveillance, on the age at which to start surveillance for each cancer, and on frequency of subsequent surveillance. The scope of this guideline was set to determine what is currently known about the efficacy, frequency and potential methods for surveillance, for breast, thyroid, renal, endometrial or colorectal cancers in PHTS. For melanoma, the risk is not sufficiently established to consider additional surveillance at present. There is clearly an increased risk of cancers in PHTS and this guideline seeks to clarify this risk, and to suggest an approach to screening that pragmatically balances the risk of harm from the over-diagnosis of cancer with the potential benefits of early identification of cancers, based on current incomplete evidence.

### Methods

ERN Guidelines on Cancer Surveillance Guideline for Individuals PHTS consists of clinicians with expertise from clinical genetics, gynaecology, endocrinology, dermatology, radiology, gastroenterology, general surgery and affected individuals and their representatives. The Guideline Development Group was led by a Core Writing Group of ERN GENTURIS HCP Members from different Member

| Cancer               | Current risk estimates                                      | Publications |
|----------------------|-------------------------------------------------------------|--------------|
| Breast               | Cancer—lifetime up to 85%; Median age at diagnosis 38–46 years | 81% [2], 85% [6], 77% [5] |
| Thyroid              | Cancer—lifetime 35%; Median age at diagnosis 37 years; Up to 75% risk of multinodular goitre, adenomatous nodules and follicular adenomas | 21% [2], 35% [6], 38% [5] |
| Endometrial          | Cancer—lifetime up to 28%; Risk starts late 30 s–early 40 s | 19% [2], 28% [6], 2% [5] |
| Renal                | Cancer—lifetime up to 34% (mostly papillary); Risk starts late 40 s | 15% [2], 34% [6], 2% [5] |
| Colorectal           | Cancer—lifetime up to 16%; Risk starts late 30 s; More than 90% have polyps, which may be symptomatic | 16% [2], 9%, [6] 3% [5], 13% [7] |
| Skin and vascular system | Melanoma—5%; Many non-malignant lesions | 6% [6] |
States and who are recognised experts in specialised clinical practice in the diagnosis and management of PHTS. The Core Writing Group leads had joint meetings with a Patient Advisory Group composed of affected individuals and parent representatives that have experience with PHTS syndrome.

The elaboration of these guidelines then additionally involved external experts from different speciality areas relevant to the scope of the guideline.

The guidelines were developed on the basis of 131 published articles extracted from Pubmed, using the following terms: (screening [title/abstract] OR surveillance [title/abstract]) AND (PTEN [title] OR Cowden [Title]) AND “humans” [MeSH Terms].

Additional papers were requested from experts in the field and references of all the papers were considered. Papers were included if they contained any data on screening or surveillance and renal cell, thyroid, endometrial, breast or colorectal cancer in PHTS.

As is typical for many rare diseases, the volume of peer-reviewed evidence available to consider for these guidelines was small and came from a limited number of articles, which typically reported on small samples or series. To balance the weight of both published evidence and quantify the weight of expert experience and knowledge, we have used for evidence grading the following scale: (i) strong evidence: consistent evidence and new evidence unlikely to change recommendation and expert consensus; (ii) moderate evidence: expert consensus or majority decision but with inconsistent evidence or significant new evidence expected and (iii) weak evidence: inconsistent evidence AND limited expert agreement.

**Recommendations**

The agreed recommendations are summarised in Table 2.

**Breast**

There is strong evidence of an increased risk of breast cancer in women with germline PVs in PTEN [3, 5, 6]. However, there was weak evidence to address the question of which modality should be used for surveillance and how surveillance impacts on morbidity and mortality in PHTS. Published studies to date suggest that the breast cancer risk in PHTS is similar to that in women with germline PVs in BRCA1/BRCA2. Therefore, many of the recommendations are derived from the much larger evidence base which exists for those hereditary breast cancer predisposition syndromes. For those centres that wish to use mammography there is no evidence of additional incremental benefit in performing mammography more frequently than every 2 years with surveillance in the intervening years being better performed by magnetic resonance imaging (MRI).

---

| Surveillance | Interval | From age | Evidence |
|--------------|----------|----------|----------|
| Breast cancer | MRI | Yearly | 30 | Strong |
| | Mammography | Every 2 years | 40 | Moderate |
| | Risk-reducing surgery offered | – | – | Moderate |
| Thyroid cancer | Ultrasound | Yearly | 18<sup>a</sup> | Strong |
| Renal cancer | Ultrasound | Every 2 years | 40 | Moderate |
| Colorectal cancer | Baseline colonoscopy<sup>b</sup> | – | 35–40 | Moderate |
| Melanoma | Baseline skin examination<sup>c</sup> | – | 30 | Weak |
| Endometrial cancer | Not recommended<sup>d</sup> | – | – | Weak |

<sup>a</sup> Moderate evidence for age of commencement of surveillance.
<sup>b</sup> Consider further surveillance as required by the gastroenterologist.
<sup>c</sup> Consider further surveillance as required by the dermatologist.
<sup>d</sup> Consider surveillance as part of clinical trial.

---

1. Women should be screened for breast cancer

2. Surveillance for breast cancer in PHTS should use MRI (MRI should be ideally conducted between day 5 and day 12 of the menstrual cycle)

3. Surveillance for breast cancer with MRI should probably start at 30

4. Women should be screened for breast cancer annually

5. If surveillance for breast cancer in PHTS additionally includes mammography this should be undertaken no more frequently than every 2 years
Table (continued)

| Breast | No Recommendations | Grading |
|--------|---------------------|---------|
| 6      | If surveillance for breast cancer with mammography is offered this *should probably* start at 40 | Moderate |
| 7      | Risk reduction surgery *should* be offered using the same considerations as for women with germline BRCA1/BRCA2 pathogenic variants | Moderate |

**Thyroid**

There is strong evidence of an increased risk of thyroid carcinoma in PHTS with evidence that this can arise at relatively young ages [2, 3, 5, 6, 8, 9]. However, no study to date has investigated which modality should be used for surveillance or how surveillance impacts on morbidity and mortality in PHTS. Although there are occasional reported cases of children with PHTS developing thyroid carcinoma [8, 9] the evidence is weak and does not support this being frequent enough to justify the significant additional burden that would be required to screen all individuals throughout childhood. There is strong evidence that identification of early stage thyroid carcinomas in other populations leads to better outcomes [2] and that ultrasound is an appropriate modality for surveillance for thyroid carcinomas.

| Thyroid | No Recommendations | Grading |
|---------|---------------------|---------|
| 1       | Individuals *should* be offered surveillance for thyroid cancer | Strong |
| 2       | Surveillance for thyroid cancer in PHTS *should* be by US | Strong |
| 3       | Surveillance for thyroid cancer *should probably* start at 18 years | Moderate |
| 4       | Individuals *should probably* be offered surveillance for thyroid cancer annually | Moderate |

**Kidney**

There is strong evidence of an increased risk of renal cell carcinoma (RCC) in individuals with PHTS. However, no study to date has investigated which modality should be used for surveillance and how surveillance impacts on morbidity and mortality in PHTS. One study of 219 individuals with PHTS identified nine individuals with prevalent or incident history of RCC [10]. Histopathological review of eight of these revealed complex tumours with mixed cell types including papillary and chromophobe. There is strong evidence that identification of early stage RCCs in other populations leads to significantly better outcomes [11]. There is strong evidence, in other populations that ultrasound is an appropriate modality for surveillance for RCCs [12, 13]. It is possible that ultrasonography will miss more aggressive tumours seen in some predisposition syndromes such as Hereditary leiomyomatosis and renal cell cancer where surveillance with renal MRI is advocated [14], but at present there are insufficient data to recommend renal MRI in PHTS.

| Kidney | No Recommendations | Grading |
|--------|---------------------|---------|
| 1      | Individuals *should* be offered surveillance for renal cell carcinoma (RCC) | Moderate |
| 2      | Surveillance for RCC in PHTS *should* be by Moderate ultrasound | Moderate |
| 3      | Surveillance for RCC *should probably* start at 40. | Moderate |
| 4      | Surveillance for RCC *should probably* be at Moderate least every 2 years. | Moderate |

**Colon**

Polyps are common in PHTS, and these are typically hamartomas, although other types can also occur [15, 16] There is weak evidence regarding colorectal cancer risk in PHTS with some studies observing a modest increased risk estimated to be 9–16% [3, 6, 15, 16], but this is not a consistent finding [5]. In the studies that showed an association the mean age at diagnosis of colorectal cancer varied from 44 to 58 years. Therefore, the recommendations for surveillance are broadly those that apply to the general population, with the addition of a baseline colonoscopy undertaken at 35-40 to assess polyp load. Further surveillance would be determined by the findings at baseline colonoscopy; if this was normal (no polyps) then general population screening guidelines should be followed.

| Colon | No Recommendations | Grading |
|-------|---------------------|---------|
| 1     | Baseline colonoscopy should be undertaken Moderate at 35–40 years to assess polyp load. | Moderate |
Colon

No Recommendations | Grading
---|---
2 If the baseline colonoscopy is normal, individuals *probably should not* be screened for colorectal cancer at any greater frequency or earlier age than the general population. | Moderate

Skin

There is weak evidence regarding skin cancer risk in *PHTS*. Therefore, the recommendations for surveillance should be those that apply to the general population, with the addition of a baseline skin examination at 30 by a dermatologist who can determine whether further surveillance is required and whether this should be done by a specialist or generalist.

| No Recommendations | Grading |
|---|---|
| 1 Individuals *probably should* have a baseline skin examination at age 30, further surveillance as required (consider every 2 years). | Weak

Endometrial

There is weak evidence regarding endometrial cancer risk in *PHTS*. The limited evidence suggests that if these cancers occur, they behave similarly to endometrial cancers in other cancer syndromes. If surveillance for endometrial cancer is offered it should be as part of a clinical trial. Women should be advised to report red flag symptoms (e.g. post menopausal or irregular vaginal bleeding) without delay so they are promptly investigated.

| No Recommendations | Grading |
|---|---|
| 1 Women *should probably not* be screened for moderate endometrial cancer. | Moderate
| 2* If surveillance for endometrial cancer is offered it *should* be as part of a clinical trial. | Strong
| 3* If surveillance for endometrial cancer is offered, it *should probably* start at 40. | Weak

4* If surveillance for endometrial cancer is offered, it should probably be done at least annually. | Weak

5 There is no clinical indication for endometrial cancer risk reduction surgery (hysterectomy). | Weak

*NB: Recommendations 2–5, should be undertaken as part of a clinical trial.

Discussion

The goal of cancer surveillance is to detect cancer at an earlier stage than symptomatic presentation, when interventions have a better chance of being curative. The proposed surveillance recommendations for PHTS require a coordinated multidisciplinary approach and significant patient commitment. It is also important to remember that individuals with PHTS are at risk of multiple cancers over their lifetime and surveillance for second cancers should not be overlooked. As this is a very rare condition there is unlikely to be a large health economic burden for the health service if these guidelines are implemented. However, surveillance in each individual is complex and additional resources may need to be put in place for those health service providers that are planning to offer surveillance at a local and regional level. For this reason, we recommend that individuals who are at 50% risk of a PTEN PV initially proceed with genetic testing to determine whether or not they require surveillance. For individuals that meet the diagnostic criteria for PHTS, but where no PV has been identified, surveillance should be tailored on a case by case base, taking into account the personal and family history of cancer. PHTS-related cancers are predominately adult onset and no specific recommendations have been made for non-malignant manifestations in adults or for the paediatric PHTS population whose management has been addressed elsewhere [17].

The evidence base for cancer surveillance in this guideline are limited. The quality of the evidence regarding baseline risk has been rated as weak as it is non-randomised and based on small numbers. A better understanding of the age-related penetrance and the extent of the risk increase of cancer is critical to improve risk counselling and risk-based recommendations for cancer prevention and treatment. We therefore recommend that national and international registries are established to collect prospective data on PHTS individuals undergoing surveillance.
Research should focus on understanding factors affecting the risk of each type of cancer and translate this into more accurate and personalised cancer risk estimates. There are no data regarding preventative drugs (e.g. tamoxifen for breast cancer, aspirin for bowel polyps/cancer) in PHTS. Furthermore, research is needed to gain insights into the cancer treatment and prognosis of PHTS patients. At present cancer treatment of PHTS patients is similar to that for sporadic cancers. Understanding the relation between patient, tumour and treatment characteristics would be the first step towards developing a tailored treatment for PHTS patients. As PHTS is a rare disease, collaboration supported by a common/central PHTS registry infrastructure is essential to underpin this. In addition, the role of prophylactic surgery has not been evaluated for this syndrome and requires further research.

Patient education is a critical component of effective cancer surveillance. This relates to both prevention (healthy living and avoidance of cancer-causing behaviours) and early detection (awareness of red flag symptoms for the key cancers). Patient information groups can assist greatly with these aspects and are a powerful resource for individuals with PHTS.

Early detection and surveillance of hereditary cancers relies on established imaging methods such as ultrasonography and MRI. It is imperative that new surveillance techniques are developed, that are not only more specific in their detection ability, but also more easily available and affordable for the healthcare systems. Utilisation of non-invasive “liquid biopsy” technologies able to identify the presence of genetic material from cancer cells in the blood or molecular markers in urine or saliva that can identify precursor lesions or cancer at its earliest stages are still being evaluated in a research setting and individuals with PHTS would be a good target population to trial these. Another area of need is the identification and validation of biomarkers that may distinguish aggressive, life-threatening cancers from more indolent types. Above all, it will be important to prospectively evaluate the effectiveness of surveillance in the PHTS population and to foster global collaborations with data sharing to enhance clinical care and research opportunities for this group of high-risk individuals.

Website

The complete guidelines can be downloaded from the ERN website: https://www.genturis.eu.

Acknowledgements The authors thank Matt Bolz-Johnson and Tom Kenny for logistic support, coordination of the guideline committee meetings and facilitating the guideline development process. They also acknowledge their colleagues from the ERN GENTURIS for fruitful discussions and suggestions. RS acknowledges funding from Wellcome Trust (210752/Z/18/Z), MT acknowledges funding from Cancer Research UK (CanGene-CanVar Catalyst Award C61296/A27223) and PTEN Research. This guideline has been supported by the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS)—Project ID No. 739547. ERN GENTURIS is partly co-funded by the European Union within the framework of the Third Health Programme “ERN–2016—Framework Partnership Agreement 2017–2021”.

The PHTS guideline development group Tanya Bisseling1, Virginie Bubien2, Frederic Caux2, Nathalie Chabbert-Buffet5, Chrystelle Colas2, Sophie Da Mota Gomes8, Martin Gotthard10, Nicoine Hoogerbrugge4, Marleen Kets11, Katherine L. Lachlan12, Therpa R. Links13, Michel Longy6, Ritse Mann10, Sjaak Pouwels1, Leo Schultze Kool10, Robert K. Semple11, Ian Stock9, Marc Tischkowitz1, Janet Vos4

1Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands; 2Cancer Genetics Unit, Institut Bergonié, Bordeaux, France; 3Dermatology, Avicenne Hospital, Assistance Publique–Hôpitaux de Paris, Université Paris 13, Bobigny, France; 4Department of Obstetrics and Gynaecology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris, Sorbonne University, Paris, France; 5Patient Representative, Paris, France; 6Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; 7Family Cancer Clinic, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; 8Wessx Clinical Genetics Service, University Hospitals Southampton NHS Trust, Southampton, UK; 9Endocrinology, University Medical Centre Groningen, Groningen, The Netherlands; 10Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK; 11Patient Representative, PTEN UK and Ireland Patient Group (PTENUKI), London, UK

The European Reference Network GENTURIS Nicoine Hoogerbrugge4, Marjolijn Ligtenberg5, Rianne Oostenbrink12, Rolf Sijmons17, Gareth Evans14, Emma Woodward19, Marc Tischkowitz1, Eamonn Maher1, Rosalie E. Ferner1, Stefan Aretz10, Isabel Spier10, Verena Steinke-Lange1, Elke Holinski-Feder1, Evelin Schött2, Thierry Frebourg2, Claudia Houdayer10, Chrystelle Colas2, Pierre Wolkenstein10, Vincent Bours2, Eric Legius26, Bruce Poppet2, Kathleen Claes27, Robin de Putter2, Ignacio Blanco Guillermino28, Gabriel Capella29, Joan Brunet Vidal30, Conxi Lázaro28, Judith Balmaña28, Hector Salvador Hernandez29, Carla Oliveira30, Manuel Teixeira30, Svetlana Bajalica-Lagercrantz22, Emma Tham1, Jan Lubinski32, Karolina Ertmanska32, Bela Melegh33, Mateja Kraje34, Ana Blatnik34, Sirkku Peltonen35, Marja Hietala35.

3Erasmus Medical Center, Rotterdam, The Netherlands; 4University Medical Center, Groningen, The Netherlands; 5Genomic Medicine, Central Manchester Foundation Trust, Manchester, UK; 6Guy’s and St. Thomas’ NHS Foundation Trust, London, UK; 7University Hospital Bonn, Bonn, Germany; 8Medizinisch Genetisches Zentrum, Munich, Germany; 9Hereditary Cancer Syndrome Center Dresden, Dresden, Germany; 10Rouen University Hospital, Rouen, France; 11University Hospital Henri Mondor-National Referral Center, Créteil, France; 12University Hospital Liege, Belgium; 13University Hospital Leuven, Leuven, Belgium; 14Ghent University Hospital, Ghent, Belgium; 15Hospital Universitari Germans Trias i Pujol y ICO Badalona, Institut Catala d’Oncologia, Barcelona, Spain; 16Hospital Sant Joan de Déu, Barcelona, Spain; 17Porto Comprehensive Cancer Center, Porto, Portugal; 18Karolinska University Hospital, Stockholm, Sweden; 19Pomeranian Medical University - University Clinical Hospital n1, Szczecin, Poland; 20University of Pécs, Pécs, Hungary; 21Institute of Oncology, Ljubljana, Slovenia; 22Turku University Hospital, Turku, Finland
**Compliance with ethical standards**

**Conflict of interest** The content of these guidelines represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

**References**

1. Pilarski R. PTEN hamartoma tumor syndrome: a clinical overview. Cancers (Basel). 2019;11:844.
2. Riegert-Johnson DL, Gleson FC, Roberts M, Tholen K, Youngborg L, Bullock M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8:6.
3. Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Yntema HG, Evans DG, Colas C, et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam Cancer. 2014;13:57–63.
4. Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986;29:222–233.
5. Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50:255–263.
6. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400–407.
7. Mester JL, Ghosh R, Pesaran T, Huether T, Karam R, Hruska KS, et al. Gene-specific criteria for PTEN variant curation: recommendations from the ClinGen PTEN Expert Panel. Hum Mutat. 2018;39:1581–1592.
8. Plampton M, Schreiner F, Gohlke B, Kionke J, Korsch E, Kirkpatrick J, et al. Thyroid disease in children and adolescents with PTEN hamartoma tumor syndrome (PHTS). Eur J Pediatr. 2018;177:429–435.
9. Smith JR, Marqusee E, Webb S, Nose V, Fishman SJ, Shamberger RC, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. J Clin Endocrinol Metab. 2011;96:34–37.
10. Mester JL, Zhou M, Prescott N, Eng C. Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. Urology. 2012;79:1187.e1181–1187.
11. Fiori E, De Cesare A, Crotetti D, Ferraro D, Barmann C, VS A, et al. Good results of surgery for renal cell carcinoma depend on early diagnosis. The need for an extensive screening program. Ann Ital Chir. 2016;87:41–44.
12. Chiarello MA, Mali RD, Kang SK. Diagnostic accuracy of MRI for detection of papillary renal cell carcinoma: a systematic review and meta-analysis. AJR Am J Roentgenol. 2018;211:812–821.
13. Vogel C, Ziegelmuller B, Ljungberg B, Bensalah K, Bex A, Canfield S, et al. Imaging in suspected renal-cell carcinoma: systematic review. Clin Genitourin Cancer. 2019;17:e345–e355.
14. Forde C, Lim DHK, Alwan Y, Burghel G, Butland L, Cleaver R, et al. Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals. Eur Urol Oncol. 2019;5:2588–9311:30161-0. [https://doi.org/10.1016/j.euo.2019.11.002](https://doi.org/10.1016/j.euo.2019.11.002).
15. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139:1927–1933.
16. Stanich PP, Owens VL, Sweetser S, Kambhatha S, Smyrk TC, Richardson RL, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clin Proc. 2011;86:489–492.
17. Macken WL, Tischkowitz M, Lachlan KL. PTEN Hamartoma tumor syndrome in childhood: a review of the clinical literature. Am J Med Genet C Semin Med Genet. 2019;181:591–610.